Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

First-Line Venetoclax and a Hypomethylating Agent or Conventional Chemotherapy in Older Adults with IDH -Mutated AML

Ian Bouligny, Graeme Murray, Thuy Ho, Juhi Gor, Kyle Zacholski, Nolan Wages, Steven Grant, Keri Maher

Blood (2023) 142 (Supplement 1): 1488.

https://doi.org/10.1182/blood-2023-188400

Published: 2023

Journal Articles

Impact of COVID-19 Pandemic on Overall Survival in Acute Myeloid Leukemia: A Comprehensive Cancer Center Experience of 627 Patients

Juhi Gor, Ian Bouligny, Thuy Ho, Graeme Murray, Keri Maher

Blood (2023) 142 (Supplement 1): 7437.

https://doi.org/10.1182/blood-2023-190759

Published: 2023

Journal Articles

Comprehensive Molecular Stratification of Patients with AML Treated with CPX-351

Thuy Ho, Juhi Gor, Graeme Murray, Ian Bouligny, Keri Maher

Blood (2023) 142 (Supplement 1): 6006.

https://doi.org/10.1182/blood-2023-187655

Published: 2023

Journal Articles

Comparison of Response and Survival with Chemotherapy and Targeted Therapies between IDH mut Isoforms in Acute Myeloid Leukemia

Ian Bouligny, Graeme Murray, Thuy Ho, Juhi Gor, Kyle Zacholski, Nolan Wages, Steven Grant, Keri Maher

Blood (2023) 142 (Supplement 1): 6010.

https://doi.org/10.1182/blood-2023-188362

Published: 2023

Journal Articles

Clinical Significance of Clonal Evolution: A Comparison of Relapsed Versus Refractory Acute Myeloid Leukemia

Graeme Murray, Ian Bouligny, Thuy Ho, Juhi Gor, Keri Maher

Blood (2023) 142 (Supplement 1): 4310.

https://doi.org/10.1182/blood-2023-185146

Published: 2023

Journal Articles

CPX-351 Versus FLAG-IDA with or without Venetoclax in Previously Untreated and Relapsed or Refractory Acute Myeloid Leukemia

Ian Bouligny, Graeme Murray, Thuy Ho, Juhi Gor, Kyle Zacholski, Nolan Wages, Steven Grant, Keri Maher

Blood (2023) 142 (Supplement 1): 4269.

https://doi.org/10.1182/blood-2023-189184

Published: 2023

Journal Articles

The Impact of Delayed Venetoclax Initiation on Overall Survival in Acute Myeloid Leukemia

Ian Bouligny, Graeme Murray, Thuy Ho, Juhi Gor, Kyle Zacholski, Nolan Wages, Steven Grant, Keri Maher

Blood (2023) 142 (Supplement 1): 4233.

https://doi.org/10.1182/blood-2023-188249

Published: 2023

Journal Articles

Revisiting Ratify: Daunorubicin 60 Mg/m 2 Vs 90 Mg/m 2 in Previously Untreated FLT3 mut Acute Myeloid Leukemia

Ian Bouligny, Graeme Murray, Thuy Ho, Juhi Gor, Kyle Zacholski, Nolan Wages, Steven Grant, Keri Maher

Blood (2023) 142 (Supplement 1): 5912.

https://doi.org/10.1182/blood-2023-189138

Published: 2023

Journal Articles

CUX1 mut Acute Myeloid Leukemia As a Distinct Biological Entity: An Analysis of Clinical Outcomes and Implications

Ian Bouligny, Graeme Murray, Thuy Ho, Juhi Gor, Kyle Zacholski, Nolan Wages, Steven Grant, Keri Maher

Blood (2023) 142 (Supplement 1): 5978.

https://doi.org/10.1182/blood-2023-189407

Published: 2023

Journal Articles

Impact of Recent Advancements in Relapsed/Refractory Acute Myeloid Leukemia on Overall Survival in Clinical Practice

Thuy Ho, Juhi Gor, Graeme Murray, Ian Bouligny, Keri Maher

Blood (2023) 142 (Supplement 1): 1474.

https://doi.org/10.1182/blood-2023-185132

Published: 2023

Journal Articles

Recent Advancements in Acute Myeloid Leukemia Have Led to Incremental Improvement in Overall Survival

Thuy Ho, Graeme Murray, Juhi Gor, Ian Bouligny, Keri Maher

Blood (2023) 142 (Supplement 1): 5187.

https://doi.org/10.1182/blood-2023-183022

Published: 2023

Journal Articles

Toward a Measurable Residual Disease-Based Algorithm for Selection of Allogeneic Hematopoietic Stem Cell Transplant in Acute Myeloid Leukemia

Thuy Ho, Juhi Gor, Ian Bouligny, Graeme Murray, Keri Maher

Blood (2023) 142 (Supplement 1): 7090.

https://doi.org/10.1182/blood-2023-182190

Published: 2023

Journal Articles

Validation of the Charlson Comorbidity Index Model in Acute Myeloid Leukemia Treated with a Hypomethylating Agent and Venetoclax

Ian Bouligny, Graeme Murray, Thuy Ho, Juhi Gor, Kyle Zacholski, Nolan Wages, Steven Grant, Keri Maher

Blood (2023) 142 (Supplement 1): 5093.

https://doi.org/10.1182/blood-2023-189322

Published: 2023

Journal Articles

FLT3 Inhibitors in Combination with FLAG-IDA in Relapsed or Refractory Acute Myeloid Leukemia

Ian Bouligny, Graeme Murray, Thuy Ho, Juhi Gor, Kyle Zacholski, Nolan Wages, Steven Grant, Keri Maher

Blood (2023) 142 (Supplement 1): 5920.

https://doi.org/10.1182/blood-2023-188333

Published: 2023

Journal Articles

The Molecular Landscape of Acute Myeloid Leukemia with Trisomy 8: A Comprehensive Cancer Center Analysis of 627 Patients

Ian Bouligny, Graeme Murray, Thuy Ho, Juhi Gor, Kyle Zacholski, Nolan Wages, Steven Grant, Keri Maher

Blood (2023) 142 (Supplement 1): 6053.

https://doi.org/10.1182/blood-2023-189260

Published: 2023

Journal Articles

IDH1/2 mut for the Win: Comprehensive Molecular Stratification of Venetoclax in Combination with Hypomethylating Agents in AML

Ian M. Bouligny, Graeme Murray, Valerie Tran, Juhi Gor, Yiwei Hang, Yanal Alnimer, Kyle Zacholski, Chad Venn, Keri Maher

Blood (2022) 140 (Supplement 1): 6335–6336.

https://doi.org/10.1182/blood-2022-170907

Published: 2022

Journal Articles

Back in JAK - Real-World Analysis of JAK mut AML

Ian M. Bouligny, Graeme Murray, Valerie Tran, Juhi Gor, Yiwei Hang, Yanal Alnimer, Kyle Zacholski, Chad Venn, Keri Maher

Blood (2022) 140 (Supplement 1): 11812–11813.

https://doi.org/10.1182/blood-2022-171165

Published: 2022

Journal Articles

Efficacy of Hypomethylating Agents with Venetoclax in TP53 mut AML

Ian M. Bouligny, Graeme Murray, Valerie Tran, Juhi Gor, Yiwei Hang, Yanal Alnimer, Kyle Zacholski, Chad Venn, Keri Maher

Blood (2022) 140 (Supplement 1): 11842–11843.

https://doi.org/10.1182/blood-2022-170972

Published: 2022

Journal Articles

Healthcare Disparities Among African Americans Are Pervasive in the Treatment of AML

Ian M. Bouligny, Graeme Murray, Valerie Tran, Juhi Gor, Yiwei Hang, Yanal Alnimer, Kyle Zacholski, Chad Venn, Keri Maher

Blood (2022) 140 (Supplement 1): 5281–5282.

https://doi.org/10.1182/blood-2022-171063

Published: 2022

Journal Articles

CPX-351 Appears Superior to 7+3 in Adverse-Risk AML and AML-MRC

Ian M. Bouligny, Graeme Murray, Valerie Tran, Juhi Gor, Yiwei Hang, Yanal Alnimer, Kyle Zacholski, Chad Venn, Keri Maher

Blood (2022) 140 (Supplement 1): 11745–11746.

https://doi.org/10.1182/blood-2022-171129

Published: 2022

NARROW

First-Line Venetoclax and a Hypomethylating Agent or Conventional Chemotherapy in Older Adults with IDH -Mutated AML

Impact of COVID-19 Pandemic on Overall Survival in Acute Myeloid Leukemia: A Comprehensive Cancer Center Experience of 627 Patients

Comprehensive Molecular Stratification of Patients with AML Treated with CPX-351

Comparison of Response and Survival with Chemotherapy and Targeted Therapies between IDH mut Isoforms in Acute Myeloid Leukemia

Clinical Significance of Clonal Evolution: A Comparison of Relapsed Versus Refractory Acute Myeloid Leukemia

CPX-351 Versus FLAG-IDA with or without Venetoclax in Previously Untreated and Relapsed or Refractory Acute Myeloid Leukemia

The Impact of Delayed Venetoclax Initiation on Overall Survival in Acute Myeloid Leukemia

Revisiting Ratify: Daunorubicin 60 Mg/m 2 Vs 90 Mg/m 2 in Previously Untreated FLT3 mut Acute Myeloid Leukemia

CUX1 mut Acute Myeloid Leukemia As a Distinct Biological Entity: An Analysis of Clinical Outcomes and Implications

Impact of Recent Advancements in Relapsed/Refractory Acute Myeloid Leukemia on Overall Survival in Clinical Practice

Recent Advancements in Acute Myeloid Leukemia Have Led to Incremental Improvement in Overall Survival

Toward a Measurable Residual Disease-Based Algorithm for Selection of Allogeneic Hematopoietic Stem Cell Transplant in Acute Myeloid Leukemia

Validation of the Charlson Comorbidity Index Model in Acute Myeloid Leukemia Treated with a Hypomethylating Agent and Venetoclax

FLT3 Inhibitors in Combination with FLAG-IDA in Relapsed or Refractory Acute Myeloid Leukemia

The Molecular Landscape of Acute Myeloid Leukemia with Trisomy 8: A Comprehensive Cancer Center Analysis of 627 Patients

IDH1/2 mut for the Win: Comprehensive Molecular Stratification of Venetoclax in Combination with Hypomethylating Agents in AML

Back in JAK - Real-World Analysis of JAK mut AML

Efficacy of Hypomethylating Agents with Venetoclax in TP53 mut AML

Healthcare Disparities Among African Americans Are Pervasive in the Treatment of AML

CPX-351 Appears Superior to 7+3 in Adverse-Risk AML and AML-MRC

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only